Document is current
Any future updates will be listed below
-
Authors
Strunz, Benedikt
Hengst, Julia
Deterding, Katja
Manns, Michael P.
Cornberg, Markus
Ljunggren, Hans-Gustaf
Wedemeyer, Heiner
Björkström, Niklas K. https://orcid.org/0000-0002-0967-076X
- License Information
-
More Information
Article History
Received: 20 April 2017
Accepted: 15 May 2018
First Online: 11 June 2018
Competing interests
: K.D. has received consulting fee, lecture fee, or honorarium from AbbVie, Gilead, and Merck/MSD; M.P.M. from AbbVie, Bristol-Myers Squibb, Gilead, Glaxo Smith Kline, Janssen, Merck/MSD, Novartis, and Roche; M.C. from AbbVie, Bristol-Myers Squibb, Gilead, Merck/MSD, and Roche; and H.W. from AbbVie, Abbott, BMS, Gilead, Janssen, Merck/MSD, and Novartis. B.S., J.H., H.G.L., and N.K.B declare no competing interests.
